Sitagliptin in Renal Transplant Recipients

Phase 4

Completed

• Conditions: Glucose Intolerance
• Interventions: Drug: sitagliptin; Drug: placebo

• Registration Number: NCT00740363
• Lead Sponsor: University of Oslo School of Pharmacy

Brief Summary

The major cause of premature death in renal transplant recipients is cardiovascular disease. Sitagliptin stimulates insulin secretion and inhibits glucagon release, two central mechanisms in PTDM by interaction with a hormone system (incretins) that just recently it has become possible to modulate by drugs. Sitagliptin therefore is an interesting additional drug for the treatment of posttransplant diabetes mellitus in transplanted patients.

The primary objective of the present study is to investigate the effect of sitagliptin on insulin secretion in renal transplant recipients.

Secondary objectives are to study the effect on insulin sensitivity, fasting blood glucose, endothelial function, CsA/Tac blood concentrations.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-08-21
• Study First Submitted QC: 2008-08-22
• Study First Posted: 2008-08-25
• Study Start: 2008-09
• Primary Completion: 2012-06
• Study Completion: 2012-06
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-21
• Last Update Posted: 2012-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Renal transplant recipient more than 1 year posttransplant with stable renal function (less than 20% deviation in serum creatinine the last 2 months) and stable prednisolone dose for the last 3 months before inclusion.

• Patients in need of (additional) oral anti-diabetic treatment:

  • New onset diabetes patients with fasting plasma glucose 7-8 mmol/ l, and/or 2-hr plasma glucose 12-18 mmol/l after an oral glucose tolerance test (OGTT)
  • Patients already on oral hypoglycemic therapy, but with HbA1c 8-11%

• 18 years of age.

• Male patient, or female patient without childbearing potential (surgically sterilized or postmenopausal) or, if female of childbearing potential, is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 Days following discontinuation of the Study Drugs.

• Signed informed consent.

Exclusion Criteria

• Treatment with insulin
• Severe liver disease.
• Estimated GFR < 25 ml/min/1.73 m2.
• Skin disorders that may influence laser Doppler flowmetry investigations.
• Pregnant or nursing mothers.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
A	sitagliptin	Patients will receive 4 weeks of treatment with sitagliptin once daily
B	placebo	No treatment for 4 weeks

Primary Outcome Measures

Name	Time	Method
Insulin secretion	4 weeks

Secondary Outcome Measures

Name	Time	Method
Insulin sensitivity	4 weeks
Fasting blood glucose	4 weeks
Endothelial function	4 weeks
Cyclosporine/tacrolimus blood concentrations	4 weeks

Trial Locations

Locations (1)

Rikshospitalet Medical Center; 🇳🇴 Oslo, Norway